Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated (NASDAQ: ARAY) pioneers precision radiation therapy systems that redefine cancer treatment standards. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of radiation oncology.
Track all essential updates in one place, including earnings announcements, regulatory milestones, and technological breakthroughs related to flagship platforms like CyberKnife and Radixact. Our curated feed simplifies monitoring of partnership agreements, research collaborations, and market expansion efforts critical to understanding Accuray's position in medical technology.
Discover comprehensive coverage of operational updates, leadership changes, and product enhancements that impact clinical workflows and patient outcomes. The resource is designed to help stakeholders assess Accuray's progress in developing adaptive radiotherapy solutions with real-time tumor tracking capabilities.
Bookmark this page for streamlined access to verified information about ARAY, including innovation roadmaps and quality control certifications. Check regularly for objective reporting on developments influencing radiation oncology practices worldwide.
Accuray Incorporated (NASDAQ: ARAY) reported strong financial results for Q3 fiscal 2023, ending March 31, 2023. Net revenue reached $118.1 million, a 22.8% increase year-over-year, while GAAP net income was $0.6 million, compared to a loss of $1.0 million in the prior year. Adjusted EBITDA surged to $8.3 million, up 53.5%. The company shipped a record 30 systems, marking a 67% growth from the previous year. However, gross product orders were $73.8 million, down from $88.6 million in the same quarter last year, and order backlog decreased by 12.7% to $506.6 million. Fiscal year guidance remains steady, with a focus on continued innovation and strategic partnerships.
FAQ
What is the current stock price of Accuray Incorp (ARAY)?
What is the market cap of Accuray Incorp (ARAY)?
